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2-methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency is a novel inborn error of isoleucine degra-
dation. In this article, we report the elucidation of the molecular basis of MHBD deficiency. To this end, we purified
the enzyme from bovine liver. MALDI-TOF mass spectrometry analysis revealed that the purified protein was
identical to bovine 3-hydroxyacyl-CoA dehydrogenase type II. The human homolog of this bovine enzyme is a
short-chain 3-hydroxyacyl-CoA dehydrogenase, also known as the “endoplasmic reticulum–associated amyloid-b
binding protein” (ERAB). This led to the identification of the X-chromosomal gene involved, which previously
had been denoted “HADH2.” Sequence analysis of the HADH2 gene from patients with MHBD deficiency revealed
the presence of two missense mutations (R130C and L122V). Heterologous expression of the mutant cDNAs in
Escherichia coli showed that both mutations almost completely abolish enzyme activity. This confirms that MHBD
deficiency is caused by mutations in the HADH2 gene.
Degradation of the branched-chain amino acid isoleu-
cine in humans takes place in mitochondria via the con-
certed action of a series of enzymes, during which iso-
leucine first undergoes transamination to 2-keto-3-
methylbutyrate, followed by oxidative decarboxylation
to 2-methylbutyryl-CoA. Like any 2-methyl branched-
chain fatty acid, 2-methylbutyryl-CoA undergoes further
breakdown by b-oxidation via a four-step pathway in-
volving dehydrogenation to tiglyl-CoA, hydration to 2-
methyl-3-hydroxybutyryl-CoA, dehydrogenation to 2-
methylacetoacetyl-CoA, and finally, thiolytic cleavage to
produce acetyl-CoA plus propionyl-CoA.
Numerous patients with a defect in isoleucinemetabo-
lism have been described in literature. In most of these
patients, the defect is at the level of the last enzyme of
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the degradation pathway; that is, 2-methylacetoacetyl-
CoA thiolase (b-ketothiolase) (MIM 203750). The en-
zymatic and molecular basis of this defect has been stud-
ied in detail (Mitchell and Fukao 2001). Patients with
2-methylacetoacetyl-CoA thiolase deficiency typically
suffer from intermittent, severe ketoacidosis with vom-
iting and hematemesis. Patients usually develop normally,
although a minority of patients show severe clinical ab-
normalities that may progress to coma and death. Pa-
tients with b-ketothiolase deficiency usually excrete tig-
lylglycine, 2-methyl-3-hydroxybutyrate, and 2-methyl-
acetoacetate in excess amounts.
Recently, two novel defects in the isoleucine break-
down pathway have been described in single patients,
including 2-methylbutyryl-CoA dehydrogenase deficiency
(MIM 600301) (Gibson et al. 2000) and 2-methyl-3-
hydroxybutyryl-CoA dehydrogenase deficiency (MHBD
deficiency [MIM 300256]) (Zschocke et al. 2000). The
first patient with MHBD deficiency (patient 1) (table 1)
was born at term and recovered well from an episode of
metabolic decompensation and lactic acidosis (Zschocke
et al. 2000). Psychomotor development was only mod-
erately delayed at age 1 year, but the patient subsequently
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Table 1
MHBD Activity in Cultured Skin Fibroblasts, Mutation Analysis of HADH2, and the Effect of the Mutations on MHBD
Protein
SUBJECT SEX
MHBD ACTIVITY
(nmol/min1.mg1)
MUTATION ANALYSIS
MUTATION
IN EXONcDNA gDNA Protein
Patient:
1 M .6 388CrT 388CrT R130C 4
2 F 1.0 388CrT 388CrC/T R130C 4
3 M .6 388CrT 388CrT R130C 4
4 M .7 NDa 388CrT R130C 4
5 M 1.8 364CrG 364CrG L122V 4
Controls ( )np 15 7.1  0.8
NOTE.—MHBD activity in cultured skin fibroblasts and mutation analysis of the coding gene from patients with MHBD
deficiency. MHBD activity in skin fibroblasts was measured spectrophotometrically in the reverse direction by following the
decrease in absorbance at 340 nm at 37C. The standard reaction medium with a total volume of 250 ml contained the
following components: 50 mM MES/100 mM potassium phosphate buffer pH 6.5, 0.1% (wt/vol) Triton X-100, 0.1 mM
NADH, and 0.2 mg/ml fibroblast homogenate protein. Reactions were started by the addition of 2-methyl-acetoacetyl-CoA
at a final concentration of 0.05 mM. Activity is given as a mean of two independent measurements. Results from controls
is given as mean  SD (number of cell lines studied).
a ND p not done.
showed a gradual loss of mental and motor skills, which
progressed with profound developmental regression,
choreoathetosis, near blindness, and epilepsy. BrainMRI
showed a slight frontotemporal atrophy. These clinical
symptoms differ markedly from those observed in pa-
tients with b-ketothiolase deficiency. Subsequently, ad-
ditional patients suffering from MHBD deficiency have
been identified.
The patients studied in the present report have all been
described before: patient 1 in Zschocke et al. (2000),
patients 2 and 3 in Ensenauer et al. (2002), and patients
4 and 5 in Poll-The et al. (2001) and Sass and Sperl
(2001), respectively. Virtually all patients identified so
far show neurological abnormalities, including psycho-
motor retardation and loss of mental and motor skills,
with the exception of patient 5, who had psychomotor
retardation but no progressive loss of mental and motor
skills. Patients with MHBD deficiency excrete excess
amounts of tiglylglycine and 2-methyl-3-hydroxybutyr-
ate, although 2-methylacetoacetate is absent in urine.
To elucidate the molecular basis of MHBD deficiency,
we purified 2-methyl-3-hydroxyacyl-CoA dehydrogenase
from bovine liver, elaborating on earlier work by Schulz
and coworkers, who were the first to show that the con-
version of 2-methyl-3-hydroxybutyryl-CoA to 2-meth-
ylacetoacetyl-CoA is brought about by a distinct 3-hy-
droxyacyl-CoA dehydrogenase (Luo et al. 1995; Mao et
al. 1995). The final purification protocol consists of a
series of four standard liquid chromatography steps; re-
sults are summarized in table 2. The purified protein
was analyzed using SDS-PAGE (Laemmli 1970), fol-
lowed by silver staining (Rabilloud et al. 1988). The re-
sult, shown in figure 1, revealed that bovine liverMHBD
is a protein with an apparent molecular weight of 28
kDa. Attempts to directly sequence the protein by Ed-
man degradation failed, probably because of a blocked
N-terminus. To resolve this problem, a different strategy
was chosen, and the 28-kDa protein band was digested
in gel with trypsin after SDS-PAGE and subjected to
MALDI-TOF mass spectrometry analysis. For this pur-
pose, ∼5 mg of purified bovine liver MHBD was loaded
on a 12% SDS-PAGE gel. After electrophoresis and CBB
R250 staining, protein-containing gel slices were S-al-
kylated, digested with trypsin (Roche Molecular Bio-
chemicals, sequencing grade), and extracted as described
elsewhere (Shevchenko et al. 1996). Extracted peptides
were purified and concentrated using Zip-Tips (Milli-
pore). Peptides were eluted from the Zip-Tips with 10
ml of 1% formic acid, 60% acetonitrile. The peptide
solution was mixed with an equal volume of 10 mg/ml
a-cyano-4-hydroxycinnamic acid (Sigma Chemical) so-
lution in acetonitrile/ethanol (1:1, vol/vol). Aliquots of 0.5
ml were spotted on the target and allowed to dry at room
temperature. MALDI-TOFMS spectra were acquired on
a Micromass TofSpec 2EC (Micromass, Wythenshawe),
equipped with a 2-GHz digitizer. The resulting peptide
spectra were used to search a nonredundant protein se-
quence database (Swiss-Prot/TrEMBL) using the Pro-
teinprobe program. Using this method, we were able to
identify MHBD as bovine 3-hydroxyacyl-CoA dehy-
drogenase type II (HADH2) (Swiss-Prot: locus HCD2_
BOVIN, accession number O02691), with 12 of the 14
peptides matching and a coverage percentage of 62%
(data not shown). This protein sequence was subse-
quently used as query to screen the human EST database,
which led to the identification of its presumed human
homolog, which has been described before as a short-
chain 3-hydroxyacyl-CoA dehydrogenase, also known
as the “endoplasmatic reticulum–associated amyloid b-
binding” protein (ERAB [GenBank accession numbers
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Figure 1 Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) analysis of bovine liver MHBD. MHBD was
purified from bovine liver and analyzed using SDS-PAGE (Laemmli
1970) followed by silver staining (Rabilloud et al. 1988). Lane 1,
molecular weight markers; Lane 2, purified bovine liver MHBD.
Table 2
Summary of the Purification of MHBD from Bovine Liver
Protein
(mg)
Specific Activity
(mmol/min.mg)
Total Activity
(mmol/min) Purification Factor
Recovery
(%)
Supernatant 347.8 .28 98.3 1 100
S-Sepharose FF CL-6B 52.4 .90 47.4 3.2 48.2
Hydroxylapatite CHT-II 4.3 3.92 17.1 14 17.4
Blue-Sepharose CL-6B 1.1 51.8 5.7 185 5.8
HiTrap butyl FF .6 53.0 3.2 189 3.3
NOTE.—All steps were performed at 4C. Approximately 10 g of bovine liver was minced and homogenized in a buffer containing 10 mM
MES pH 6.0, 10% (vol/vol) glycerol, 2 mM DTT, and 100 mM KCl, using a Potter-Elvehjem homogenizer. After sonication, the homogenate
was centrifuged at for 1 h at 4C, and the supernatant was diluted with a buffer containing 10 mM MES pH 6.0, 10% (vol/vol)20,000# gav
glycerol and 2 mM DTT. This was loaded on an S-Sepharose FF CL-6B column ( cm; Pharmacia Biotech), and bound proteins were1.6# 10.5
eluted from the column using a linear gradient of KCl in the same buffer up to a final concentration of 400 mM. Fractions were collected and
assayed for MHBD activity, as described elsewhere (Zschocke et al. 2000). Protein concentrations were determined, as described elsewhere,
using bovine serum albumin as standard (Bradford 1976). Fractions with MHBD activity were pooled, diluted in a 20-mM potassium phosphate
buffer (pH 7.4) containing 10% (vol/vol) glycerol and 5 mM DTT, and loaded on a 5-ml hydroxylapatite CHT-II column (Biorad). Bound
proteins were eluted with a linear gradient of potassium phosphate up to a final concentration of 300 mM. Fractions with highest MHBD
activity were pooled, diluted in a 20-mM potassium phosphate buffer pH 7.4 containing 10% (vol/vol) glycerol and 5 mM DTT, and loaded
on a Blue-Sepharose CL-6B column (Pharmacia Biotech). The column was developed with a linear gradient of KCl up to a final concentration
of 1 M. Fractions with highest MHBD activity were pooled, and an equal volume of a 20-mM potassium phosphate pH 7.4 buffer containing
10% (vol/vol) glycerol, 5 mM DTT, and 3 M ammonium sulfate was added slowly. After 1 h on ice, aggregates were removed by centrifugation
at for 10 min. The supernatant was loaded on a 1-ml HiTrap butyl FF column (Pharmacia Biotech) equilibrated with a solution10,000# gav
containing 20 mM potassium phosphate pH 7.4 buffer containing 10% (vol/vol) glycerol, 5 mM DTT, and 1.5 M ammonium sulfate. After
sample application, the column was washed and developed with linear gradient of ammonium sulfate to a final concentration of 0 M. Fractions
were collected, assayed for MHBD activity, and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), as described
elsewhere (Laemmli 1970), followed by silver staining (Rabilloud et al. 1988).
U96132 and AF037438]). The gene involved is located
on the X-chromosome and contains 6 exons (GenBank
accession number NM_004493 [Xp11.2, gi:4758503]).
On the basis of the nucleotide sequence of the human
gene, primers were selected and used for the amplifi-
cation of HADH2 from both cDNA and genomic DNA
(table 3). First-strand cDNA synthesis was performed as
described (IJlst et al. 1994), using 5–10 mg of total RNA
isolated from cultured human skin fibroblasts. MHBD-
encoding cDNA was amplified from first-strand cDNA
as template in two overlapping fragments. Fragment 1:
“21M13 forward”-tagged 21HADH2 plus “M13
reverse”-tagged 497HADH2; fragment 2: “21M13
forward”-tagged 352HADH2 plus “M13 reverse”-
tagged 837HADH2. PCR conditions for each primer
set were 94C for 2 min; followed by 30 cycles of 94C
for 30 s, 55C for 30 s, and 72C for 1 min; and a final
extension step at 72C for 2 min. Subsequent sequence
analysis of these PCR fragments, using both sense and
antisense strands, was performed using “21M13 for-
ward” and “M13 reverse” fluorescent primers on an
Applied Biosystems 377A automated sequencer, accord-
ing to the manufacturer’s protocol. For mutation analy-
sis at the genomic level, DNAwas purified from cultured
skin fibroblasts, using the Promega Wizard Genomic
DNA purification kit, or from blood spots, using Chelex,
as described elsewhere (Walsh et al. 1991). The gene was
amplified in three fragments using the following primer
sets: fragment 1: “21M13 forward”-tagged Ex1/2frw
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Figure 2 Detection of HADH2 388CrT mutation by RFLP
analysis. The zygosity of the 388CrT mutation found in patients 2
and 3 (table 1) was studied using RFLP analysis. Genomic DNA was
amplified using the primers 2284HADH2frw plus “M13 reverse”-
tagged Ex3/4rev. PCR conditions were as described for the other ge-
nomic DNA amplifications. After amplification, the PCR products
were incubated for 2 h at 37C in the presence () or absence () of
10 units of BglII, and, afterward, the restriction products were sep-
arated on a 2% agarose gel.
Table 3
Primers Used for Amplification and Cloning of Human HADH2
Primer Amplification
“21M13 forward”-tagged 21HADH2 5′-tgtaaaacgacggccagtCGTGGAGTGGCCGGCGAC-3′
“M13 reverse”-tagged 497HADH2 5′-caggaaacagctatgaccTCCAACCTGACCCTCGAAGG-3′
“21M13 forward”-tagged 352HADH2 5′-tgtaaaacgacggccagtCATACCTTGGAAGACTTCCAG-3′
“M13 reverse”-tagged 837HADH2 5′-caggaaacagctatgaccAAAGGAAGGGCAGAGGAGC’-3′
“21M13 forward”-tagged Ex1/2frw 5′-tgtaaaacgacggccagtCGTGGAGTGGCCGGCGAC-3′
“M13 reverse”-tagged Ex1/2rev 5′-caggaaacagctatgaccTGACCTCATGCACACCCTGG-3′
“21M13 forward”-tagged Ex3/4frw 5′-tgtaaaacgacggccagtGAGATGAATACCTTCTCCAC-3′
“M13 reverse”-tagged Ex3/4rev 5′-caggaaacagctatgaccagatctAGAGTAGAAGTCATAGGTGG-3′
“21M13 forward”-tagged Ex5/6frw 5′-tgtaaaacgacggccagtATGCCTCCTAAGTGACTTG-3′
“M13 reverse”-tagged Ex5/6rev 5′-caggaaacagctatgaccAAAGGAAGGGCAGAGGAGC-3′
2284HADH2 frw 5′-TGGGCACCTTCAATGAGATC-3′
BamHI-tagged forward primer 5′-aaaggatccaaaATGGCAGCAGCGTGTCGGAG-3′
HindIII-tagged reverse primer 5′-aaaaagcttTCAAGGCTGCATACGAATGGC-3′
NOTE.—On the basis of the nucleotide sequence of the human gene, primers were selected and used for the
amplification of HADH2 from both cDNA and genomic DNA. The 2284HADH2frw primer contains a
mismatch (single underlined) which creates a BglII-restriction site in combination with the HADH2 388CrT
mutation. The Ex3/4rev primer has an internal BglII restriction site (bold italics) to function as a control.
Restriction sites for BamHI and HindIII are shown in italics.
plus “M13 reverse”-tagged Ex1/2rev; fragment 2:
“21M13 forward”-tagged Ex3/4frw plus “M13 re-
verse”-tagged Ex3/4rev; fragment 3: “21M13 for-
ward”-tagged Ex5/6frw plus “M13 reverse”-tagged
Ex5/6rev. PCR conditions for each primer set were 2
min at 96C for 2 min; followed by 30 cycles of 96C
for 30 s, 55C for 30 s, and 72C for 2 min; and a final
extension step at 72C for 2 min. Subsequent sequence
analysis of these PCR fragments, using both sense and
antisense strands, was performed as described above.
The results of the sequence analysis of HADH2 from
the patients with MHBD deficiency are shown in table
1. In all patients, mutations were identified in their
HADH2 cDNA, which could be confirmed by genomic
DNA analysis. One missense mutation (C388CrT), re-
sulting in the substitution of the arginine residue at po-
sition 130 for a cysteine (R130C), was identified in four
of the five patients (patients 1–4) (table 1). The predomi-
nance of one missense mutation in a severe X-chro-
mosomal disorder was unexpected. There is no indica-
tion that the families of our patients are related. Cytosine
at position 388 is part of a CpG dinucleotide that may
be methylated and, thus, could represent a mutation hot
spot in theHADH2 gene. Family histories of the affected
patients were unremarkable. At least one carrier for the
388CrT mutation is asymptomatic. As expected for an
X-chromosomal gene, all mutations observed in the
cDNA from the male patients (patients 1, 3, 4, and 5)
were found to be hemizygous at the genomic level. In
the female patient (patient 2), the mutation was found
in a heterozygous form at the genomic level, evident
from RFLP analysis, as shown in figure 2. In patient 5,
a 364CrG mutation was found, which results in the
substitution of the leucine residue at position 122 for a
valine (L122V). RFLP analysis was used to screen for
the 364CrG mutation in the family of patient 5. The
results, presented in figure 3, clearly show that the
mother is heterozygous for the 364CrG mutation,
whereas the mutation is not found in the other members
of the family. MHBD is a member of the short-chain
dehydrogenase family (conserved domain database at
NCBI: pfam00106.6, adh_short), and both missense
mutations, R130C and L122V, are within the conserved
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Figure 3 Detection of the HADH2 364CrG mutation by RFLP
analysis in a family with MHBD deficiency. The presence of the
364CrG mutation found in patient 4 (table 1) was studied in other
family members (father, mother, brother, and sister) and two unrelated
control subjects. Therefore, fragment 2 was amplified from genomic
DNA, followed by an incubation in the presence () or absence ()
of the restriction enzyme HinfI. Finally, the restriction fragments were
separated on a 2% agarose gel.
Figure 4 Immunological detection of MHBD in cultured skin
fibroblasts from patients with MHBD deficiency. For immunoblot
analysis, 50 mg protein of cultured skin fibroblasts from control sub-
jects and patients with MHBD deficiency was applied on a 10% poly-
acrylamide gel and separated, as described elsewhere (Laemmli 1970).
After electrophoresis, proteins were transferred to a nitrocellulose
membrane by semidry blotting, probed with the polyclonal antibody
raised against recombinant human MHBD, and developed (Wanders
et al. 1995). After staining of the blot with NBT/BCIP, the result was
digitalized by use of a desktop scanner and the amount of MHBD
protein quantified, using the National Insitutes of Health Image 1.62
software program. CRIM p cross reactive immunological material.
Control-mean value of three control subjects represented as 100%
(SD); 1p patient 1; 2p patient 2; 3p patient 3, and 5p patient
5 (see table 1).
domain. However, it is not knownwhether these residues
are involved in enzyme activity. Amino acid sequence
comparison of humanMHBDwith members of this fam-
ily revealed that both residues are not highly conserved.
To determine the effect of these mutations on enzyme
stability or activity, we first performed immunoblot analy-
sis of MHBD in cultured skin fibroblasts from our group
of patients. For antigen preparation, wild-type human
MHBD was expressed in E. coli as a maltose-binding
protein (MBP) fusion protein. To this end, the complete
ORF of human wild-type HADH2 was amplified by use
of Taq DNA polymerase, with the BamHI-tagged for-
ward primer and HindIII-tagged reverse primer (table
3). The PCR program used for amplification started with
2 min of denaturation at 94C; followed by 25 cycles
of 30 s at 94C, 30 s at 55C, and 1.5 min at 72C; and
a final extension step at 72C for 2 min. The PCR prod-
uct was cloned downstream of the isopropyl-1-thio-D-
galactopyranoside (IPTG)-inducible PTAC promoter into
the BamHI and HindIII sites of the bacterial expression
vector pMAL-C2X (New England Biolabs) to express
MHBD as a fusion protein with MBP. The complete ORF
was sequenced to exclude sequence errors introduced
during PCR. Transformed bacteria (INVa) were grown
in 100-ml LB medium, supplemented with 100 mg/ml
ampicillin to an OD600 of ∼0.5, and IPTG was added to
a final concentration of 1 mM to induce protein ex-
pression. After 4 h at 37C, cells were pelleted and re-
suspended in 20 ml 10-mM sodium phosphate buffer
pH 7.4, containing 140 mMNaCl, 0.1% (wt/vol) Triton
X-100, and protease inhibitors (2 tablets Completemini
[Boehringer Mannheim]). The fusion protein was subse-
quently purified from the supernatant, according to the
protocol of the manufacturer (New England BioLabs),
and stored at 20 C.
Antibodies were raised in rabbits using 100 mg fusion
protein per injection, as described elsewhere (Jansen et
al. 2000). The result of the immunoblot (fig. 4) revealed
that, in all patients with the 388CrT mutation, the
amount of MHBD protein is decreased. Apparently, the
R130C substitution has a strong effect on MHBD sta-
bility and probably results in a more rapid degradation
of the enzyme. In the patient with the 364CrG muta-
tion, no significant decrease in the amount of MHBD
protein could be observed. Next, heterologous expres-
sion studies in E. coli were performed to determine the
effect of the substitutions on enzyme activity. The result,
depicted in figure 5, shows that the R130C mutation
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Figure 5 Heterologous expression of human MHBD in E. coli.
The complete ORF of HADH2 from a control subject and from pa-
tients with MHBD deficiency were amplified and ligated into the bac-
terial expression vector pMAL-C2X, as described. Each ORF was se-
quenced to exclude sequence errors introduced during PCR.
Transformed bacteria (INVa) were grown in 20-ml LB medium sup-
plemented with 100 mg/ml ampicillin to an OD600 of ∼0.5, and IPTG
was added to a final concentration of 1 mM to induce protein ex-
pression. After 4 h at 37C, cells were pelleted and resuspended in 1
ml 10 mM sodium phosphate buffer pH 7.4, containing 140 mM
NaCl, 0.1% (wt/vol) Triton X-100 and protease inhibitors (1 tablet
Completemini [Boehringer Mannheim] in 10-ml solution). Lysis was
achieved by sonication at 9 W for 10 s. The bacterial lysate was
centrifuged for 10 min at av, and the pellet was discarded.14,000# g
The supernatant was used for protein measurement and MHBD ac-
tivity, as described. Expression levels of the fusion protein in the bac-
terial extracts were equal, on the basis of immunoblot analysis (data
not shown). pMAL p expression with empty pMAL-c2x vector;
pHADH2 p expression with vector containing the wild-type human
MHBD; pHADH2 388CrT p expression of human MHBD mutant
with R130C; pHADH2 364CrG p expression of human MHBD
mutant with L122V.
leads to a fully inactive enzyme, whereas some residual
activity amounting to 2%–3% of the wild-type enzyme
was found in the case of the L122Vmutant. These results
indicate that the R130C substitution affects both enzyme
stability and activity, whereas the L122V substitution
mainly effects enzyme activity. This explains the high
residual MHBD activity (∼25% of the controls) found
in the patient with the L122V substitution and could
account for the milder clinical presentation of MHBD
deficiency in this patient, compared with the male pa-
tients with the R130C mutation. The clinical phenotype
of the female patient with the R130C mutant is also
milder, compared with the male patients with this mu-
tation, although residual MHBD activity in their cul-
tured skin fibroblasts is comparable.However, theMHBD
activity measured in the female patient does not properly
reflect the amount of MHBD activity present in other
tissues. We believe that, because her clinical phenotype
is less severe than that of the male patients, her wild-
type allele is silenced, owing to X-chromosome inacti-
vation, in most but not all body tissues.
In conclusion, we have resolved the molecular basis
of 2-methyl-3-hydroxybutyric aciduria through the iden-
tification of mutations in the HADH2 gene coding for
MHBD. This is the first known organic aciduria that is
inherited as an X-chromosomal trait. The exact func-
tions of the MHBD protein, apart from its role in iso-
leucine metabolism, are unclear. The protein was first
identified during a two-hybrid screen by its ability to bind
to amyloid-b peptide (Ab), a neurotoxic peptide impli-
cated in the pathogenesis of Alzheimer disease (MIM
104300) (Yan et al. 1997). The protein, was named “en-
doplasmic reticulum–associated Ab-binding protein”
(ERAB), since it was found predominantly at the en-
doplasmic reticulum. Its expression was found to be in-
creased in the brain of patients with Alzheimer disease,
and ERAB facilitated Ab cytotoxicity in neuroblastoma
and transfected COS cells in vitro. Independent studies
by He et al. (1998) had led to the identification of the
same protein as the human homolog of bovine L-3-hy-
droxyacyl-CoA dehydrogenase type II, which was pu-
rified and cloned by Hashimoto and coworkers (Ko-
bayashi et al. 1996; Furuta et al. 1997).
The exact role of this 3-hydroxyacyl-CoA dehydrog-
enase in mitochondrial fatty acid b-oxidation remained
unclear at that time, especially since mitochondria are
known to already contain two different 3-hydroxyacyl-
CoA dehydrogenases for short- and long-chain substrates
(see Wanders et al. [1999] and Rinaldo et al. [2002] for
review), which are expressed in all tissues. It has also
been shown that the enzyme also harbors 17b/3a-hy-
droxysteroid dehydrogenase activity toward steroid hor-
mones, and, accordingly, the enzyme has been referred
to as “17b-hydroxysteroid dehydrogenase type 10” (He
et al. 1999). The reactivity of the enzyme with 2-methyl-
3-hydroxyacyl-CoA esters, as reported in the present
study, adds another function to this protein. The sub-
cellular localization of the protein in mitochondria,
rather than in the endoplasmic reticulum, as demon-
strated convincingly by several groups (Frackowiak et
al. 2001), is in line with the role of MHBD/ERAB in
isoleucine metabolism.
The link among MHBD, Alzheimer disease, and the
neurodegeneration observed in patients with MHBD de-
ficiency remains unclear. It has been reported that the
enzymatic activity of ERAB is central to its capacity to
potentiate Ab toxicity; indeed, a catalytically crippled
form of ERAB was ineffective (Yan et al. 1999). In con-
trast, it has also been reported that deposition of Alz-
heimer vascular amyloid-b is associated with decreased
rather than increased expression of brain ERAB (Ghaedi
et al. 1999). On the other hand, high levels of the enzyme
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were found in hippocampal synaptic mitochondria in
transgenic mice that overexpress b-amyloid protein pre-
cursor, a model organism of Alzheimer disease, suggesting
a possible pathogenetic link between the enzyme and
disturbed metabolism of intraneuronal steroid hormones
(He et al. 2000). Further work is required to clarify the
functional role of MHBD. It appears likely that the mul-
tifunctional capacities of the enzyme are at the basis of
the unusual clinical abnormalities observed in MHBD-
deficient patients as compared with b-ketothiolase de-
ficient patients.
Note added in proof.—More detailed information on
patient 5 can be found in the paper entitled “2-Methyl-
3-Hydroxybutyryl-CoA Dehydrogenase Deficiency: Im-
paired Catabolism of Isoleucine Presenting as Neuro-
degenerative Disease,” by Jo¨rn Oliver Sass, Rosemarie
Forstner, and Wolfgang Sperl, which was accepted for
publication in Brain and Development after acceptance
of the present paper.
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